Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer
Phase NA
Enrollment 140
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Rationale: Women with hormone-receptor positive breast cancer are usually prescribed endocrine therapy for a period of 5-10 years. This treatment reduces the risk of recurrence and improves overall survival in these women. Musculoskeletal complaints are a common (\~50%) negative consequence of endocrine treatment, which affects daily functioning and quality of life. These symptoms frequently result in early treatment discontinuation, which is associated with shorter disease-free survival. Musculoskeletal complaints are often pharmacologically treated with limited effect and accompanied by side-effects. Therefore, interventions to counteract musculoskeletal complaints are urgently needed in this population. A potential non-pharmacological option is yoga. In patients with osteoarthritis, there is emerging evidence that yoga is effective to reduce pain and stiffness and improve function. Yoga as treatment for musculoskeletal complaints that are associated with endocrine treatment is rarely investigated and mainly in small studies. Objective: The objective of the proposed study is to assess the effectiveness of a 4-month yoga program compared to a waiting list control group on musculoskeletal complaints in women with hormone-positive stage I-III breast cancer receiving endocrine treatment who report musculoskeletal complaints. Study design: The COBRA study is a randomized controlled trial with two study arms: a yoga- and a waiting list control group. Study population: For this study, 140 women with oestrogen-receptor positive stage I-III breast cancer on endocrine treatment (aromatase inhibitors or Tamoxifen; \>4 months) will be recruited. These women experience musculoskeletal complaints (\>3 months) which started or exacerbated after initiation of endocrine treatment. Furthermore, eligible women did not practice yoga in the last six months and are not planning to start yoga and are not highly physically active (i.e., \>150 minutes per week moderate-vigorous exercise). Intervention: The intervention consists of two one-hour sessions/week supervised yoga and once a week 30-minute yoga exercises at home. The 4-month yoga program will be an active form of yoga, such as Easy Vinyasa yoga, which is characterized by continuous slow movements linked with breathing. The waiting list control patients will be offered an online yoga program after the 4-month study period.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: live yoga — following live yoga classes twice a week and using yoga video's at home once a week
  • Behavioral: live remote yoga — The control group will be offered live remote yoga classes after the intervention period

Primary Outcomes

  • Musculoskeletal complaints (Baseline, at 4 and 8 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-08
Completion: 2027-06
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: false
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UMC Utrecht
Collaborators: World Cancer Research Fund International
Principal Investigators:
  • Anne May, Prof. Dr. (STUDY_DIRECTOR) - UMC Utrecht
Contact Information
Study Contact:
Evelyn Monninkhof, Dr.
+31623786177
e.monninkhof@umcutrecht.nl
Stefanie Veenhuizen, MSc
+31631119129
s.g.a.veenhuizen@umcutrecht.nl
Stefanie Veenhuizen, MSc
+31 6 31 11 91 29
s.g.a.veenhuizen@umcutrecht.nl
University Medical Center Utrecht (UMC Utrecht)
Interventions
  • Behavioral: live yoga — following live yoga classes twice a week and using yoga video's at home once a week
  • Behavioral: live remote yoga — The control group will be offered live remote yoga classes after the intervention period
Study Locations (1 sites)
University Medical Center Utrecht (UMC Utrecht), Utrecht, 85500 3508 GA Netherlands
Eligibility Criteria
Inclusion Criteria: * Be diagnosed with oestrogen-receptor positive stage I-III breast cancer, * Use of aromatase inhibitors or Tamoxifen (\>4 months and will continue using it for at least six months), * Have finished primary treatment (chemotherapy, radiotherapy, surgery) for at least 12 weeks, * Experience musculoskeletal complaints (\>3 months, which are at least mild in severity (i.e., score of ≥ 3 for worst pain item of a modified version of the Brief Pain Inventory \[BPI\](16, 42))., which started or exacerbated after initiation of endocrine treatment, * Be stabilized on menopausal symptom medication or antidepressants for at least three months and three weeks, respectively, if applicable, and * Be able to read, speak and understand Dutch or English. Exclusion Criteria: * Too physically active (i.e., \>150 minutes/week of self-reported moderate-to-vigorous or leisure and sports activities) * Following (during the last 6 months), or planned to follow yoga classes on a structural base * Following, or planned to follow, a structured psychological intervention during the intervention period, i.e., cognitive behavioral therapy, or unstable on psychotropic medication * Participated in the intervention group of an exercise study during breast cancer treatment * Any circumstances that would impede ability to give informed consent or adherence to study requirements as determined by the study team * More than 3 weeks not able to attend training sessions during the intervention period * A body mass index (BMI) of \>35 kg/m2
Conditions HER2-Positive Breast Carcinoma
Phase Not Applicable
Enrollment 81
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study assesses the effect of hormone directed treatment for breast cancer on glucose metabolism.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Non-Interventional Study — Non-Interventional Study

Primary Outcomes

  • Disposition Index (DI) (Baseline; up to 1 year)
  • Glucose homeostasis - tamoxifen compared to no treatment (Baseline; up to 1 year)
  • Glucose homeostasis - aromatase inhibitor compared to tamoxifen (Baseline; up to 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-11-16
Completion: 2026-12-01
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: true
Enrollment: 81 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Kalpana Muthusamy, MBBS, MD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic in Rochester
Contact Information
Study Contact:
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Mayo Clinic in Rochester
Kalpana Muthusamy, MBBS, MD
Mayo Clinic in Rochester
Interventions
  • Other: Non-Interventional Study — Non-Interventional Study
Study Locations (1 sites)
Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria: * Post-menopausal women with hormone receptor positive breast cancer, ductal carcinoma in situ (DCIS), or with other high risk breast conditions. Post-menopause will be defined as women who experience 12 months of amenorrhea or have undergone bilateral salpingo-oophorectomy. * 25 women who are planning to start or are within 6 months of starting treatment with aromatase inhibitors, after consultation in breast clinic and cancer center. * 25 women who will be starting Tamoxifen (comparative group) * 25 healthy post menopausal women will also be recruited. Exclusion Criteria: * Established diagnosis of diabetes * Therapy with medications that could affect glucose metabolism * Screening fasting glucose ≥ 126 mg/dl, and/or HbA1c ≥ 6.5% * History of upper GI surgery that alters gastric emptying or causing malabsorption e.g., bariatric surgery, fundoplication
Conditions Breast Neoplasms
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In the context of breast cancer, in case of an indication for chemotherapy, anthracycline-based protocols make it possible to improve the overall survival of patients most at risk. The frequency of anthracycline-related cardiac toxicities (ARCT) increases with the cumulative dose of anthracyclines administered and explains, at least in part, the increased risk of cardiovascular (CV) mortality in patient populations treated for breast cancer. The numerous indications for anthracycline-based protocols have made it possible to describe ARCT, among which heart failure with reduced left ventricular ejection fraction (LVEF) remains one of the most comorbid. In addition to left ventricular dysfunction, anthracyclines have been associated with endothelial dysfunction, microvascular damage and myocardial ischemia responsible for dilated cardiomyopathy. Different approaches have attempted to better understand and prevent these ARCT. However, apart from the notion of limit cumulative doses of anthracyclines, few of them have made it possible to screen patients at risk and prevent the onset of cardiac dysfunction. The search for biological markers (Troponin I, BNP) or ultrasound markers (Longitudinal Strain) warning of subclinical cardiac damage is still struggling to assert its interest due in particular to significant inter- and intra-observer variability. Therapeutically, ACE inhibitors and beta-blockers have shown a significant improvement in the incidence rate of LVEF reduction during adjuvant treatment of breast cancer. However, despite equivalent signals in other cancers, the studies conducted to date are insufficiently powered and the role of these treatments is limited to secondary prevention or the treatment of objective heart failure. It remains necessary to determine new biological markers that can identify patients most at risk of ARCT and thus adapt our therapeutic prevention strategies. To do this, it is first necessary to better understand the pathophysiology underlying these ARCT. The objective of this study is to determine whether expression of the receptor among endothelium and circulating cells, SGLT2, is associated with an additional risk of presenting cardiovascular toxicity following treatment with anthracycline. If this association is demonstrated, it will then be possible to better screen and prevent these cardiovascular complications.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Anthracycline — as standard of care

Primary Outcomes

  • Evaluate the expression of SGLT2 (At cycles 1, 2, 3, 4 and 2-3 weeks after end of treatement.)
  • Evaluate the expression of SGLT2 (At cycles 1, 2, 3, 4 and 2-3 weeks after end of treatement.)
  • Evaluate the expression of SGLT2 (At cycles 1, 2, 3, 4 and 2-3 weeks after end of treatement.)
  • Evaluate the expression of SGLT2 (At cycles 1, 2, 3, 4 and 2-3 weeks after end of treatement.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-02-17
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Paul Strauss
Collaborators: Centre de Recherche en biomédecine de Strasbourg INSERM UMR-S1118
Principal Investigators:
  • Hervé BISCHOFF (PRINCIPAL_INVESTIGATOR) - Centre Paul Strauss
Contact Information
Study Contact:
Anne ANTHONY
+33(0)388252413
promotion-rc@institut-strauss.fr
MANON VOEGELIN
+33(0)3 68 33 95 23
promotion-rc@institut-strauss.fr
Hervé BISCHOFF, MD
h.bischoff@institut-strauss.fr
Centre Paul Strauss
Interventions
  • Drug: Anthracycline — as standard of care
Study Locations (1 sites)
Centre Paul Strauss, Strasbourg, France
Eligibility Criteria
Inclusion Criteria: * Patient \> 18 years old * Diagnosed with localized breast cancer * Indication for first-line surgery or anthracycline-based chemotherapy. Exclusion Criteria: * History of chemotherapy or targeted therapy or immunotherapy administered before inclusion * Patient currently being treated with anti-SGLT2, conversion enzyme inhibitor or ARA2 * Patient with known heart disease (ischemic, rhythmic, valvular, etc.) * Patient with a Glomerular filtration rate \< 45 mL/min/1.73m² according to the pre-therapeutic assessment * Patient with impaired liver function * Patient who is pregnant or breastfeeding * Patient with a second cancer undergoing treatment * Patient under guardianship or curatorship, protection of justice or deprived of liberty
Conditions Breast Cancer, Microcalcification, Image
Phase Not Applicable
Enrollment 350
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Conventional mammography, breast sonography and breast MRI have specific weaknesses. In particular, mammography has a low sensitivity for the detection of mammary carcinoma in patients with a dense breast. Phase contrast mammography could help to overcome some of these limitations. Observational study.

Design

Study type: Observational Observational model: Other Time perspective: Other

Interventions / Regimen

  • Diagnostic Test: Experimental Intervention — Mammography in the radiology department is commonly performed using General Electrics Medical Systems Senographe Essential device

Primary Outcomes

  • Sensitivity and specificity of PCM compared to FFDM represent the primary outcome since the limited sensitivity of mammography, in particular in patients with dense breasts, represents the major limitation of the currently applied FFDM. (30 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-10-17
Completion: 2030-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 350 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Zurich
Collaborators: Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland, GratXray AG
Principal Investigators:
  • Thomas Frau, Prof (PRINCIPAL_INVESTIGATOR) - University Hospital Zurich, DIR
Contact Information
Study Contact:
Thomas Frauenfelder, Prof
+41 44 255 93 83
thomas.frauenfelder@usz.ch
Judith Jehle
0763257051
judith.jehle@usz.ch
Thomas Frauenfelder, PD MD
0041442551111
thomas.frauenfelder@usz.ch
University Hospital Zurich - Diagnostic Radiology
Interventions
  • Diagnostic Test: Experimental Intervention — Mammography in the radiology department is commonly performed using General Electrics Medical Systems Senographe Essential device
Study Locations (2 sites)
University Hospital Zurich - Diagnostic Radiology, Zurich, Canton of Zurich 8091 Switzerland
University of Zurich, Zurich, Switzerland
Eligibility Criteria
Inclusion Criteria: * Inclusion criteria -Phase 0: * \>18 years * Mastectomy, tumorectomy or biopsy planned * Informed consent of the patient Inclusion criteria -Phase 1: * \>18 years * BI-RADS 5 (highly suggestive of malignancy at ultrasound or mammography) or 6 (known biopsy proven malignancy); * Scheduled for mastectomy or breast conserving surgery with radiotherapy. * Informed consent of the patient Inclusion criteria - Phase 2: * \>40 years * undergoing mammography for screening or diagnostic purpose. * Informed consent of the patient Exclusion Criteria: * Exclusion criteria for all three Phases: * Breast implants. The women will be asked, if they have a breast-implant. * Inability to understand the study procedure due to cognitive or linguistic deficits. Exclusion criteria for patients, participating in Phase 1 and Phase 2: * Pregnancy * Breast-feeding. * Re-staging after neoadjuvant chemotherapy. Patients who participated in prior research projects with ionizing radiation in the past 12 months
Conditions Pulmonary Artery Hypertension
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a multi-center, perspective, and exploratory study aimed at evaluating the 3-years clinical outcome of Potts-shunt procedure for pediatric patients with severe pulmonary artery hypertension (PAH). The included criteria are as followed: 1)6 months \< age ≤ 18 years; 2) ESC 2022 Group I PAH; 3) Have received standardized drug therapy for at least 6-9 months and still remain at intermediate to high/high-risk status of the criteria of ESC2022; 4) Presenting with significant clinical manifestations (i.e., progressive symptoms/syncope history/growth and development restriction, etc); 5) Informed consent form signed by the patient and their guardian. The excluded criteria are as followed: 1) ESC 2022 Group II-V PAH; 2) Poor right ventricular function: RVEF \< 25% or RVFAC \< 20%; 3) Deteriorated general condition: requiring ICU resuscitation or ECMO assistance; 4) Pulmonary artery pressure/main arterial pressure ratio \< 0.7; 5) Six-minute walk distance \< 150 meters (only applicable to patients aged 8 and above); 6) No significant improvement in RVEF under triple drug therapy. All of the pediatric patients with severe PAH who attend to pediatric cardiac outpatient clinic and meet the designed included criteria and excluded criteria will be enrolled in this study. All of the participants will be divided into two groups (Potts-shunt combined with conventional drug therapy group and only conventional drug therapy group) according to their individual health status (i.e., some contraindications of surgery) and their (or their parents') aspiration for Potts-shunts procedure. Follow-up is designed (eight-times follow-up) at the time of Potts-shunt procedure, post-operative ICU period, one month, three months, six months, one year, two years, and three years after Potts-shunt procedure or the rejection of Potts-shunt procedure. The items of follow-up include state of survival, whether or not have the lung transplantation (LTx), clinical manifestation, laboratory examination, function of right ventricle (detected by echocardiogram and cardiac magnetic resonance imaging), and the pulmonary circulation pressure (detected by right heart catheterization or Swan-Ganz catheterization). Primary outcome is the incidence rates of death or LTx three-years after Potts-shunt. Secondary outcomes are as followed: 1) Number and incidence rate of postoperative complications in patients undergoing Potts-shunt procedure; 2) Three-year WHO cardiac functional and 6-minute walk distance after Potts-shunt procedure; 3) the NT-ProBNP levels three-years after Potts-shunt procedure; 4) Right ventricular function on echocardiography three years after Potts-shunt procedure; 5) Right ventricular function on cardiac magnetic resonance imaging three years after Potts-shunt procedure; 6) Pulmonary circulation pressure measured by right heart catheterization or Swan-Ganz catheterization three years after Potts-shunt procedure; 7) Three-year mortality or LTx incidence rates after only…

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Comprehensive therapy combined Potts-shunt procedure and conventional drug therapy — Potts-shunt procedure is the surgery that connect the descending aorta and the left/main pulmonary artery by direct anastomosis, a Gore-tex tube or a Gore-tex tube with flap.
  • Drug: Only conventional drug therapy — Only conventional drug therapy (i.e., Prostacyclin analogues, PDE-5 inhibitors, and Endothelin receptor antagonists)

Primary Outcomes

  • Mortality or Lung transplantation (From the date of enrollment until the date of dear from any cause or lung transplantation, which ever came first, accessed up to 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-23
Completion: 2029-04-23
Eligibility
Age: 6 Months and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: China National Center for Cardiovascular Diseases
Contact Information
Study Contact:
Shoujun Li, MD
+8613501071589
drlishoujunfw@163.com
Shoujun Li, MD
+8613501071589
drlishoujunfw@163.com
Pediatric cardic surgical center, Fuwai Hospital
Interventions
  • Procedure: Comprehensive therapy combined Potts-shunt procedure and conventional drug therapy — Potts-shunt procedure is the surgery that connect the descending aorta and the left/main pulmonary artery by direct anastomosis, a Gore-tex tube or a Gore-tex tube with flap.
  • Drug: Only conventional drug therapy — Only conventional drug therapy (i.e., Prostacyclin analogues, PDE-5 inhibitors, and Endothelin receptor antagonists)
Study Locations (1 sites)
Pediatric cardic surgical center, Fuwai Hospital, Beijing, Beijing Municipality 100037 China
Eligibility Criteria
Inclusion Criteria: 1. 6 months \&lt; age ≤ 18 years; 2. ESC 2022 Group I PAH; 3. Have received standardized drug therapy for at least 6-9 months and still remain at intermediate to high/high-risk status of the criteria of ESC2022; 4. Presenting with significant clinical manifestations (i.e., progressive symptoms/syncope history/growth and development restriction, etc); 5. Informed consent form signed by the patient and their guardian. Exclusion Criteria: 1. ESC 2022 Group II-V PAH; 2. Poor right ventricular function: RVEF \&lt; 25% or RVFAC \&lt; 20%; 3. Deteriorated general condition: requiring ICU resuscitation or ECMO assistance; 4. Pulmonary artery pressure/main arterial pressure ratio \&lt; 0.7; 5. Six-minute walk distance \&lt; 150 meters (only applicable to patients aged 8 and above); 6. No significant improvement in RVEF under triple drug therapy.

Ablative SBRT in Elderly BC Patients

NCT06523894
Recruiting
Conditions Breast Cancer
Phase NA
Enrollment 36
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Stereotactic body radiotherapy (SBRT) is a modern radiotherapy technique, through which extremely high doses of irradiation are delivered in a very precise manner, within a few fractions. SBRT is increasingly used into clinical practice because it can provide excellent local control, comparable to surgery, in many tumor locations, such as lung, liver or bone. Efforts to develop it for BC treatment are promising, as it is safe, convenient, and effective. To date, SBRT for BC has been developed as an alternative method of partial-breast irradiation (PBI) in the pre- or post-operative setting. Therefore, the doses tested are comparable to the conventional doses used with surgery although its potential as sole local treatment for BC remains unknown. Higher SBRT doses are expected to permit obtaining an ablative effect on tumor and be suitable as an alternative to surgery, but this hypothesis has yet to be tested. The aim of the present study is to prove the feasibility of SBRT as an ablative treatment in early breast cancer (BC). The primary objective is to find the maximum tolerated dose of SBRT that can be safely administered in inoperable patients with BC, the majority of whom are elderly or oldest old. The overall objective is to determine whether high precision, dose- and fractionation- adapted SBRT is feasible and safe in inoperable patients with BC. The dose and fractionation-adapted SBRT regimen permits to test feasibility in different tumor sizes. The primary objective of this study is to establish the maximum tolerated dose (MTD) that can be delivered with a single or few (up to 5) fractions of SBRT in inoperable patients with BC.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: SBRT — Adapted to tumor volume BC SBRT

Primary Outcomes

  • Maximum Tolerated Dose (MTD) (4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-25
Completion: 2029-03-25
Eligibility
Age: 70 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Geneva
Principal Investigators:
  • Pelagia Tsoutsou, Pr (STUDY_CHAIR) - Radiation Oncology Department, Geneva University Hospital
Contact Information
Study Contact:
Pelagia Tsoutsou, Pr
0795534630
pelagia.tsoutsou@hug.ch
Pelagia Tsoutsou, Pr
+41 22 372 70 93
Pelagia.Tsoutsou@hug.ch
Radiation Oncology Department, Geneva University Hospital
Interventions
  • Radiation: SBRT — Adapted to tumor volume BC SBRT
Study Locations (1 sites)
Radiation Oncology Department, Geneva University Hospital, Geneva, 1205 Switzerland
Eligibility Criteria
Inclusion Criteria: 1. Age over 70 years 2. Histologically confirmed diagnosis of BC, any time before study enrollment. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3. 4. Patient considered inoperable in multidisciplinary board decision or refusing surgery. Main criteria determining inoperability are inability to receive general anesthesia after anesthetics and/or surgical evaluation. Criteria described in the statement of American Society of Anesthesiologists (ASA) {, #4699} and American College of Surgeons Surgical risk calculators {, #4695} are usually addressed in the multidisciplinary discussion (Appendix ). 5. Presence of measurable disease in the breast, defined as a lesion that can be accurately measured in at least one dimension with imaging (ultrasound, CT or MRI). Disease in the axilla or internal mammary chain is allowed and will be treated at the discretion of the radiation oncologist. Regional disease is not considered in measurements of local response. 6. Primary tumor accessible to SBRT, as defined by treating radiation oncologist. 7. Neo-adjuvant systemic therapy is allowed. 8. Tumor size in planning computed tomography (CT) permitting SBRT delivery. SBRT appropriateness is defined by the treating radiation oncologist. 9. Multifocality (over two tumor foci within the same breast quadrant) is allowed, as long as the total treatment volumes remain suitable for SBRT, as defined by the treating radiation oncologist. 10. Total tumor treatment volume/ whole breast volume ratio not exceeding 30%. 11. Previous treatment for BC to the contralateral breast is allowed. Previous treatment to the same breast for other reason than BC is allowed. 12. Capacity of patient to collaborate for SBRT delivery. 13. Capacity of patient to understand and sign a written informed consent according to International Council for Harmonization (ICH)/Good Clinical Practice (GCP) regulations before registration. Exclusion Criteria: 1. Prior surgery for the current diagnosis. 2. Prior whole or partial breast irradiation to the involved breast. 3. Absolute contraindication to RT, such as Li-Fraumeni syndrome. 4. Current participation and receipt of study therapy or previous participation in a study of an investigational agent and receipt of study therapy or used an investigation device within 4 weeks of the first day of treatment. 5. Not able to communicate meaningfully with investigator and site staff and/or incapable of discernment. 6. Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications. \-
Conditions Asthma, Protein
Phase Not Applicable
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Asthma, a prevalent chronic respiratory affliction, significantly impinges upon the quality of life for affected individuals. Timely and appropriate diagnostic measures, coupled with efficacious therapeutic interventions, are paramount in mitigating exacerbations of symptoms and enhancing the life quality of patients. Ezrin plays an important role in maintaining cell morphology, cell migration, cell adhesion and polarisation, but Ezrin expression in airway smooth muscle remains unclear. Pip5k1α is an important kinase involved in intracellular phosphatidylinositol signalling pathways that may be involved in smooth muscle contraction and diastole. Therefore, further studies are necessary to elucidate the changes of Ezrin and Pip5k1α in patients with asthma to provide a basis for investigating alternative treatments for asthma.

Design

Study type: Observational Observational model: Case Control Time perspective: Retrospective

Interventions / Regimen

  • Other: No intervention. — Observational study with no intervention.

Primary Outcomes

  • Immunofluorescence results (6 months)
  • Immunohistochemistry results (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-05-28
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Lei-Miao Yin
Collaborators: Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 6th People's Hospital, Xiangya Hospital of Central South University, Baoshan Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai Pulmonary Hospital, Shanghai, China
Principal Investigators:
  • Lei-Miao Yin, MD (STUDY_DIRECTOR) - Yueyang Hospital, Shanghai University of Traditional Chinese medicine
  • Wei-Wei He, MD (STUDY_DIRECTOR) - Shanghai 6th People's Hospital
  • Jun-Tao Feng, MD (STUDY_DIRECTOR) - Xiangya Hospital of Central South University
Contact Information
Study Contact:
Lei-Miao Yin, MD
86 21 54592134
collegeylm@shutcm.edu.cn
Lei-Miao Yin, MD
86-21-54592134
collegeylm@shutcm.edu.cn
Yueyang Hospital, Shanghai University of Traditional Chinese Medicine
Interventions
  • Other: No intervention. — Observational study with no intervention.
Study Locations (1 sites)
Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai Municipality 200030 China
Eligibility Criteria
Inclusion Criteria: * Lung tissue samples; * The samples come from patients aged 18-70 years old, regardless of gender, who underwent lung tissue sampling for surgical indications during treatment; * Paraffin sections of lung tissue from patients diagnosed with bronchial asthma, including tracheal smooth muscle; * Paraffin sections of lung tissue from non-asthma patients, including tracheal smooth muscle. Exclusion Criteria: * Paraffin sections of lung tissue from patients who have been diagnosed with COPD; * Other situations where the researcher deems it inappropriate to participate in this study.
Conditions Healthy
Phase PHASE2
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, and the non-Hispanic Black (NHB) population is disproportionately affected. Our research has previously demonstrated that oxidative stress may contribute to reduced vascular function in otherwise healthy NHB adults, potentially predisposing them to the development of hypertension and CVD. This study is designed to examine whether the mitochondria are an important source of oxidative stress-induced vascular dysfunction in healthy NHB adults.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Dietary Supplement: MitoQ — MitoQ supplement is composed of mitoquinol mesylate, which is a synthetic analog of coenzyme Q10
  • Dietary Supplement: Placebo — MitoQ matched Placebo
  • Drug: MitoTempo — During each experimental visit, intradermal microdialysis will be used to locally infuse MitoTempo (a mitochondria-specific superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.
  • Drug: Tempol — During each experimental visit, intradermal microdialysis will be used to locally infuse Tempol (a superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.
  • Drug: L-NAME — During each experimental visit, L-NAME (nitric oxide synthase inhibitor) will be perfused through microdialysis fibers for quantification of nitric oxide-mediated vasodilation.
  • Drug: SNP - Sodium Nitroprusside — At the end of each experimental visit, SNP will be perfused through microdialysis fibers to elicit a maximal vasodilation response.

Primary Outcomes

  • Cutaneous microvascular responses to local heating (1 hour post intervention)
  • Flow-mediated dilation responses (1 hour post intervention)
  • Mitochondrial ROS production in peripheral blood mononuclear cells (PBMCs) (1 hour post intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-07-01
Completion: 2030-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Georgia
Contact Information
Study Contact:
S. Tony Wolf
706-542-4378
stwolf@uga.edu
Melissa Gorejena
mgorejena@uga.edu
Interventions
  • Dietary Supplement: MitoQ — MitoQ supplement is composed of mitoquinol mesylate, which is a synthetic analog of coenzyme Q10
  • Dietary Supplement: Placebo — MitoQ matched Placebo
  • Drug: MitoTempo — During each experimental visit, intradermal microdialysis will be used to locally infuse MitoTempo (a mitochondria-specific superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.
  • Drug: Tempol — During each experimental visit, intradermal microdialysis will be used to locally infuse Tempol (a superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.
  • Drug: L-NAME — During each experimental visit, L-NAME (nitric oxide synthase inhibitor) will be perfused through microdialysis fibers for quantification of nitric oxide-mediated vasodilation.
Study Locations (1 sites)
Ramsey Student Center, University of Georgia, Athens, Georgia 30602 United States
Eligibility Criteria
Inclusion Criteria: * Self-identify as either non-Hispanic Black or non-Hispanic White. * Men and women 18-75 years old. * Non-hypertensive (systolic blood pressure \[SBP\]\<130 and diastolic blood pressure \[DBP\] \<85 mmHg). * Have low density lipoprotein cholesterol \<150mg/dl. * Have HbA1C \<6.0%. Exclusion Criteria: * Rash, skin disease, or disorders of pigmentation (e.g., psoriasis, eczema, vitiligo, or other skin inflammatory skin disorders) * Known skin allergies to latex or adhesives * Smoking and/or use of nicotine-containing products within the past year * Use of illegal/recreational drugs * Generalized kidney disease * Taking chloramphenicol, cholestyramine, medication for seizures, methotrexate, nitrofurantoin, tetracycline, barbiturates, steroids, phenobarbital/phenytoin, orlistat or pyrimethamine * Any current medications which could conceivably alter the cardiovascular control or responses * Diagnosed or suspected metabolic or cardiovascular disease * Current pregnancy or breastfeeding * History of skin or other cancers * Diagnosed or suspected diabetes (HbA1c ≥6.0) * Anybody with narcolepsy or who has been diagnosed with any condition that impairs body temperature regulation.
Conditions Bipolar Depression, Bipolar Disorder (BD...
Phase NA
Enrollment 88
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Individuals with Bipolar Disorder (BD) have twice the risk of being affected by metabolic comorbidities and a 1.8-fold increased risk of mortality from cardiovascular diseases when compared to the general population. These factors are fundamental in the 14-year reduction in the life expectancy of people with TB reported in recent meta-analyses. This occurs mainly due to the increased inflammation associated with the disease, the adverse effects of pharmacological treatments and unhealthy lifestyle habits that are more common in people diagnosed with BD. Nutrition has been studied as an adjunctive treatment in other psychiatric disorders, but there is a lack of studies about the role of nutrition in TB. Considering that diet can impact metabolic health, this randomized controlled study aims to evaluate the effect of a nutritional intervention on cardiovascular risk in patients with TB. The intervention is based on the dietary pattern recommended in the Dietary Guidelines for the Brazilian Population and will be applied by a registered dietitian. According to the literature, the sample size will be 72 individuals with TB (36 in the control group with usual treatment + 36 in the intervention group added to the usual treatment). The intervention will be carried out in 7 individual sessions and 8 group sessions with specific themes. The primary aim of this protocol will be an intervention to contribute to cardiovascular health - verified by serum markers, anthropometric measurements and the Framingham Cardiovascular Risk Score (algorithm used to estimate an individual's 10-year cardiovascular risk). The secondary stages will be the adherence of the intervention and the impact on the quality of life of the participants. The possible positive results of this nutritional intervention can open new clinical perspectives. Meaning that might show that better food choices can protect the cardiovascular health of individuals with TB, leading to a reduction in morbidity and mortality associated with the disease.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Nutritional intervention — 7 individual sessions (online) + 6 small group sessions (1-in person + 5 online)

Primary Outcomes

  • C reactive protein (Baseline, week 12, week 24 and follow up at week 52)
  • Total cholesterol and fractions (Baseline, week 12, week 24 and follow up at week 52)
  • Glycemia (Baseline, week 12, week 24 and follow up at week 52)
  • Glycated hemoglobin A1C (Baseline, week 12, week 24 and follow up at week 52)
  • Triglycerides (Baseline, week 12, week 24 and follow up at week 52)
  • HOMA IR (Baseline, week 12, week 24 and follow up at week 52)
  • Apoliporpotein B (Baseline, week 12, week 24 and follow up at week 52)
  • Cardiovascular risk (Baseline, week 12, week 24 and follow up at week 52)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 88 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Sao Paulo
Collaborators: Deakin University
Contact Information
Study Contact:
FERNANDA GABRIEL, MS
5511999690790
fernandacg.nutri@gmail.com
Fernanda Gabriel
Interventions
  • Behavioral: Nutritional intervention — 7 individual sessions (online) + 6 small group sessions (1-in person + 5 online)
Study Locations (1 sites)
Fernanda Gabriel, São Paulo, São Paulo 04514102 Brazil
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of Bipolar disorder types I and II diagnosis * Adults of both genders, from 18 to 60 years old * In typical pharmacotherapy for BD, for at least one month * Agreement to participate in the study with signature of the consent form Exclusion Criteria: * Patients with "very good or excellent" diet quality assessed by the diet quality scale (ESQUADA): \>275 out of a score of 375 * Patients in a state of hypomania or mania: score \>8 (Young Mania Rating Scale - YMRS) * Patients with severe depression \>21 Montgomery-Åsberg Depression Rating Scale * Patients at low cardiovascular risk (\<7 points for men or \<9 points for women on the Framingham Global Risk Score) * Low weight or eutrophic body mass index: \<25kg/m² as in similar studies * Pregnant or breastfeeding women * Patients diagnosed with anorexia and bulimia nervosa * Patientes diagnosed with Irritable Bowl Syndrome or other diagnosed conditions that affect the gastrointestinal function
Conditions Pediatric Asthma, Rhinitis, Allergic, Qu...
Phase Not Applicable
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This prospective observational study aims to assess the health-related quality of life (HRQoL) of 200 children (ages 5-16) with bronchial asthma, allergic rhinitis, or both, and their 200 parents, comparing 100 children receiving specific immunotherapy with 100 receiving routine treatment. Using EQ-5D-Y(EuroQol five dimensions questionnaire, youth version), disease-specific scales, and newly developed Chinese versions of EQ-5D-Y and EQ-HWB-S (EuroQol health and well-being questionnaire, short version), the study evaluates HRQoL changes over 1 and 2 years and explores the impact on caregiver burden and spillover effects. A control group of 100 healthy children and their parents will be included. Data collection involves baseline and follow-up surveys, clinical data from medical records, and statistical analyses to compare treatment effects and validate measurement tools.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Drug: Subcutaneous immunotherapy / Standard Treatment for Asthma and Rhinitis — 1. Subcutaneous Allergen-Specific Immunotherapy: * Pre-treatment: Omalizumab subcutaneous injection, with the total IgE level serving as the basis for calculating the dosage for children. The appropriate dosage of omalizumab (each dose ranging from 75 to 600 mg) and administration frequency (once every 4 weeks) are determined based on the baseline IgE (IU/mL, measured before the start of treatment) and body weight (kg). * Mite Allergen Preparation: (Antergen/Alutard) 2. Standard Treatment: * Asthma: Inhaled corticosteroids (ICS) combined with long-acting beta-2 agonists, leukotriene receptor antagonists. * Allergic Rhinitis: Oral antihistamines, nasal antihistamines, nasal corticosteroids, anti-leukotriene drugs, cromolyn sodium, decongestants (oxymetazoline hydrochloride), and nasal saline irrigation.

Primary Outcomes

  • Asthma control level for asthmatic children (Baseline 1 week before treatment; 2 follow-up every 12 months)
  • Severity assessment of allergic rhinitis (Baseline 1 week before treatment; 2 follow-up every 12 months)
  • EQ-5D-Y-3L for assessing health-related quality of life (Baseline 1 week before treatment; 2 follow-up every 12 months)
  • EQ-VAS for assessing health-related quality of life (Baseline 1 week before treatment; 2 follow-up every 12 months)
  • PAQLQ for assessing health-related quality of life in children with asthma (Baseline 1 week before treatment; 2 follow-up every 12 months)
  • JRQLQ-No. 1 for assessing health-related quality of life in children with allergic rhinitis (Baseline 1 week before treatment; 2 follow-up every 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-07-20
Completion: 2027-05-31
Eligibility
Age: 5 Years and older
Sex: ALL
Volunteers: true
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wenjing Zhou
Principal Investigators:
  • Wenjing Zhou (PRINCIPAL_INVESTIGATOR) - Renji Hospital, School of Medicine, Shanghai Jiaotong University
Contact Information
Study Contact:
Wenjing Zhou
+31685281032
zhoujing2188@163.com
Wenjing Zhou
+31685281032
zhoujing2188@163.com
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Interventions
  • Drug: Subcutaneous immunotherapy / Standard Treatment for Asthma and Rhinitis — 1. Subcutaneous Allergen-Specific Immunotherapy: * Pre-treatment: Omalizumab subcutaneous injection, with the total IgE level serving as the basis for calculating the dosage for children. The appropriate dosage of omalizumab (each dose ranging from 75 to 600 mg) and administration frequency (once every 4 weeks) are determined based on the baseline IgE (IU/mL, measured before the start of treatment) and body weight (kg). * Mite Allergen Preparation: (Antergen/Alutard) 2. Standard Treatment: * Asthma: Inhaled corticosteroids (ICS) combined with long-acting beta-2 agonists, leukotriene receptor antagonists. * Allergic Rhinitis: Oral antihistamines, nasal antihistamines, nasal corticosteroids, anti-leukotriene drugs, cromolyn sodium, decongestants (oxymetazoline hydrochloride), and nasal saline irrigation.
Study Locations (1 sites)
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, Shanghai Municipality 200127 China
Eligibility Criteria
Inclusion Criteria: 1. Children: 1. Aged 5-16 years; 2. Diagnosed with bronchial asthma, allergic rhinitis, or both (persistent, duration ≥4 weeks) by a respiratory or allergy specialist; 3. Guardian has signed the informed consent form; 4. Able to understand and complete the questionnaire; 5. Outpatients or inpatients at the Pediatrics Department of Renji Hospital in Shanghai. 2. Parents: 1. The primary caregiver of the enrolled child; 2. Accompanied the child to the hospital on the day of the visit; 3. Signed the informed consent form; 4. Able to understand and complete the questionnaire. Exclusion Criteria: 1. Children: 1. Poor compliance; 2. Already received specific immunotherapy at another hospital; 3. Unable to independently read and complete the questionnaire; 4. Lost to follow-up or discontinued treatment. 2. Parents: 1. Unwilling to sign the informed consent form; 2. Unable to complete the questionnaire due to physical condition or educational level.
Conditions Subthreshold Depression
Phase NA
Enrollment 204
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the effects of multi-session transcranial direct current stimulation on loneliness, mood and depressiveness in people with subthreshold depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Personalized Experimental Transcranial Direct Current Stimulation (tDCS) — This study will deliver tDCS sessions for a maximum of ten sessions in two weeks' time. Participants will receive 20 minutes of active stimulation with a 2mA intensity over personalized brain regions based on the particular neural correlates of socio-affective processing.
  • Device: Sham Transcranial Direct Current Stimulation (tDCS) — This study will deliver tDCS sessions for a maximum of ten sessions in two weeks' time. Participants assigned to the sham control group will only receive 30 seconds of active stimulation.
  • Device: Conventional Experimental Transcranial Direct Current Stimulation (tDCS) — This study will deliver tDCS sessions for a maximum of ten sessions in two weeks' time. Participants will receive 20 minutes of active stimulation with a 2mA intensity with anode placed over F3.

Primary Outcomes

  • Changes in self-reported loneliness (From baseline to after the last tDCS session; from baseline to 3 months after the last tDCS session)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-16
Completion: 2027-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 204 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Education University of Hong Kong
Collaborators: The University of Hong Kong, Chinese University of Hong Kong, Hong Kong Baptist University
Principal Investigators:
  • Nichol ML Wong, PhD (PRINCIPAL_INVESTIGATOR) - Education University of Hong Kong
Contact Information
Study Contact:
Nichol ML Wong, PhD
852-29487431
nmlwong@eduhk.hk
Nichol ML Wong, PhD
852-29487431
nmlwong@eduhk.hk
The Education University of Hong Kong
Interventions
  • Device: Personalized Experimental Transcranial Direct Current Stimulation (tDCS) — This study will deliver tDCS sessions for a maximum of ten sessions in two weeks' time. Participants will receive 20 minutes of active stimulation with a 2mA intensity over personalized brain regions based on the particular neural correlates of socio-affective processing.
  • Device: Sham Transcranial Direct Current Stimulation (tDCS) — This study will deliver tDCS sessions for a maximum of ten sessions in two weeks' time. Participants assigned to the sham control group will only receive 30 seconds of active stimulation.
  • Device: Conventional Experimental Transcranial Direct Current Stimulation (tDCS) — This study will deliver tDCS sessions for a maximum of ten sessions in two weeks' time. Participants will receive 20 minutes of active stimulation with a 2mA intensity with anode placed over F3.
Study Locations (1 sites)
The Education University of Hong Kong, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * No histories of learning impairment, major psychiatric disorders including Major Depressive Disorder or neurological disorders * At least primary school education * Subthreshold depression Exclusion Criteria: * On medication or treatments within 2 weeks prior to the beginning of the study that would affect the individual's brain, cognitive and affective functions
Conditions Breast Cancer, Solid Tumor
Phase PHASE1
Enrollment 21
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is an open, multicenter, increasing dose and dose extension nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics and preliminary efficacy of BL-B16D1 in patients with unresectable locally advanced or metastatic breast cancer and other solid tumor.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BL-B16D1 — Administration by intravenous infusion for a cycle of 3 weeks.

Primary Outcomes

  • Phase Ia: Dose limiting toxicity (DLT) (Up to 21 days after the first dose)
  • Phase Ia: Maximum tolerated dose (MTD) (Up to 21 days after the first dose)
  • Phase Ib: Recommended Phase II Dose (RP2D) (Up to approximately 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-08-26
Completion: 2026-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 21 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Principal Investigators:
  • Jiong Wu (PRINCIPAL_INVESTIGATOR) - Fudan University
  • Jian Zhang (PRINCIPAL_INVESTIGATOR) - Fudan University
Contact Information
Study Contact:
Sa Xiao, PHD
15013238943
xiaosa@baili-pharm.com
Jiong Wu
Fudan University Shanghai Cancer Center
Jiong Wu
Fudan University Shanghai Cancer Center
Interventions
  • Drug: BL-B16D1 — Administration by intravenous infusion for a cycle of 3 weeks.
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality China
Eligibility Criteria
Inclusion Criteria: 1. Sign the informed consent form voluntarily and follow the protocol requirements; 2. Gender is not limited; 3. Age: ≥18 years old and ≤75 years old (stage Ia); ≥18 years old (stage Ib); 4. Expected survival time ≥3 months; 5. Patients with histologically and/or cytologically confirmed unresectable locally advanced or metastatic breast cancer and other solid tumors who failed or could not receive standard treatment; 6. Consent to provide archival tumor tissue samples or fresh tissue samples from primary or metastatic lesions within 3 years; 7. Must have at least one extracranial measurable lesion that meets the RECIST v1.1 definition; 8. ECOG 0 or 1; 9. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0; 10. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%; 11. The organ function level must meet the requirements if the patient has not received blood transfusion or hematopoietic stimulation factor therapy within 14 days before the first dose; 12. Coagulation function: international normalized ratio ≤1.5, and activated partial thromboplastin time ≤1.5ULN; 13. Urinary protein ≤2+ or ≤1000mg/24h; 14. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, serum pregnancy must be negative, and the patient must not be lactating; All enrolled patients (male or female) should use adequate contraception throughout the treatment cycle and for 6 months after completion of treatment. Exclusion Criteria: 1. Chemotherapy, biological therapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Oral drugs such as fluorouracil; 2. History of severe heart disease; 3. Prolonged QT interval, complete left bundle branch block, III degree atrioventricular block; 4. Active autoimmune and inflammatory diseases; 5. Patients with other malignant tumors or a history of other malignant tumors; 6. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; Infusion-related thrombosis was excluded; 7. Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure \&gt; 150 mmHg or diastolic blood pressure \&gt; 100 mmHg); 8. Patients with poor glycemic control; 9. Patients with grade ≥1 radiation pneumonitis according to the RTOG/EORTC definition; Previous history of ILD or current ILD, or suspicion of such disease during screening; 10. Complicated with pulmonary diseases leading to clinically severe respiratory function impairment; 11. Patients with primary central nervous system (CNS) tumors or CNS metastases that had failed local treatment; 12. Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any of BL-B16D1's excipients; 13. Received previous organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT); 14. In previous (new) adjuvant anthracyclines, the cumulative dose of anthracyclines for doxorubicin \> 550 mg/m2, epirubicin \> 900 mg/m2 or the equivalent dose of other similar drugs; 15. Human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection or active hepatitis C virus infection; 16. Serious infection occurred within 4 weeks before the first dose; Signs of pulmonary infection or active pulmonary inflammation within 2 weeks before the first dose; 17. Patients with massive or symptomatic effusions, or poorly controlled effusions; 18. Had participated in another clinical trial within 4 weeks before the first dose (calculated from the time of the last dose); 19. Had the following eye diseases: a. active infection or corneal ulcer; b. monocular vision; c. a history of corneal transplantation; d. Contact lens dependence; e. Uncontrolled glaucoma; f. Uncontrolled or progressive retinopathy, wet macular degeneration, etc.; 20. Other circumstances that the investigator deemed inappropriate for participation in the trial.